Mitsubishi UFJ Asset Management UK Ltd. Purchases 3,000 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Mitsubishi UFJ Asset Management UK Ltd. boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 12.5% during the 4th quarter, Holdings Channel reports. The fund owned 27,000 shares of the specialty pharmaceutical company’s stock after buying an additional 3,000 shares during the period. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in Supernus Pharmaceuticals were worth $976,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Armistice Capital LLC lifted its position in shares of Supernus Pharmaceuticals by 47.6% in the 2nd quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock worth $141,026,000 after purchasing an additional 1,700,000 shares during the period. Dimensional Fund Advisors LP raised its stake in Supernus Pharmaceuticals by 12.1% in the second quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock worth $76,690,000 after buying an additional 309,966 shares in the last quarter. Stephens Investment Management Group LLC lifted its holdings in Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after buying an additional 33,710 shares during the period. Pacer Advisors Inc. boosted its position in Supernus Pharmaceuticals by 29.9% during the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after acquiring an additional 403,028 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after acquiring an additional 74,438 shares in the last quarter.

Insider Activity

In other news, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the transaction, the director now directly owns 13,315 shares of the company’s stock, valued at $487,595.30. The trade was a 51.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jack A. Khattar sold 125,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the transaction, the chief executive officer now owns 926,172 shares in the company, valued at $33,971,988.96. This represents a 11.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 154,213 shares of company stock valued at $5,660,180 over the last ninety days. 9.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

SUPN has been the subject of several recent research reports. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Cantor Fitzgerald assumed coverage on shares of Supernus Pharmaceuticals in a report on Monday, January 6th. They issued an “overweight” rating and a $57.00 price target on the stock.

Supernus Pharmaceuticals Trading Up 2.2 %

Shares of SUPN opened at $38.58 on Wednesday. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $39.37. The stock has a fifty day moving average price of $36.71 and a 200-day moving average price of $33.93. The firm has a market cap of $2.13 billion, a PE ratio of 36.06 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. During the same quarter last year, the company earned ($0.29) earnings per share. The company’s quarterly revenue was up 14.2% on a year-over-year basis. As a group, research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.